Halo Biosciences Pipeline

Halo's scientific platform has the potential to support a robust pipeline of multiple indications and therapeutic modalities.

The company maintains a primary focus on its lead programs with HB-1614, a proprietary reformulation of a well characterized hyaluronan-synthesis inhibitor, 4-methylumbelliferone (4-MU). HB-1614 is planned for clinical study in 2026. 

The company is advancing its lead clinical program for HB-1614 in pulmonary hypertension and interstitial lung disease (PH-ILD) and has initiated an earlier stage development program in diabetes. 

To generate clinical proof of concept for the potential of HB-1614, the company has also advanced multiple clinical programs for H01, which is a commercially available form of 4-MU.